Lannett Advances Its Insulin Glargine

Rival To Sanofi’s Lantus Gets Positive Feedback From FDA

 
• By Akriti Seth
  
Road
Lannett will file a 351(k) biosimilar application by 2022 • Source: Shutterstock

More from Biosimilars

More from Products